Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016:2016:9324279.
doi: 10.1155/2016/9324279. Epub 2016 Aug 14.

Preliminary Evaluation of Clinical and Angiographic Outcomes with Biodegradable Polymer Coated Sirolimus-Eluting Stent in De Novo Coronary Artery Disease: Results of the MANIPAL-FLEX Study

Ranjan Shetty  1 , Jayesh Prajapati  2 , Umesh Pai  1 , Kiran Shetty  1
Affiliations

Preliminary Evaluation of Clinical and Angiographic Outcomes with Biodegradable Polymer Coated Sirolimus-Eluting Stent in De Novo Coronary Artery Disease: Results of the MANIPAL-FLEX Study

Ranjan Shetty et al. Scientifica (Cairo). 2016.

Abstract

Objective. The objective of the MANIPAL-FLEX study was to evaluate the feasibility, preliminary safety, and efficacy of the Supraflex sirolimus-eluting stent (SES) implantation, in de novo coronary artery disease, using clinical and quantitative coronary angiography (QCA) follow-ups. Methods. This was a prospective, nonrandomized, multicenter, single-arm study that enrolled 189 patients with de novo coronary artery disease who were treated with the Supraflex SES. Of 189 patients enrolled, the first 61 consecutive patients who consented to a 9-month follow-up evaluation by QCA, irrespective of presence of symptoms, were to be followed up with angiography at 9 months. The primary endpoint of the study was target lesion failure (TLF), including cardiac death, myocardial infarction, and target lesion revascularization during 12-month follow-up after the index procedure. Results. The mean age of the study population was 58 ± 11 years, with 51.3% (97/189) of hypertensive patients. Total of 66 lesions, analyzed by offline QCA, showed good scaffolding of the target vessel with in-stent late lumen loss at 9 months of 0.18 ± 0.23 mm. The observed TLF at 30-day, 6-month, and 12-month follow-up were 2 (1.1%), 6 (3.2%), and 10 (5.3%), respectively. Conclusion. This study provides preliminary evidence for the feasibility, safety, and efficacy of the Supraflex sirolimus-eluting stent.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of the study.
Figure 2
Figure 2
Supraflex sirolimus-eluting stent: a schematic view of the stent structure (circle shows flexible “S-link”).
Figure 3
Figure 3
Scanning electron microscopy (SEM) images of a (a) normal, (b) crimped, and (c) expanded Supraflex sirolimus-eluting stent.
Figure 4
Figure 4
Drug release kinetics of the Supraflex sirolimus-eluting stent.
Figure 5
Figure 5
Cumulative frequency distribution curves of in-stent minimal lumen diameter by QCA.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. The Lancet. 2007;369(9562):667–678. doi: 10.1016/s0140-6736(07)60314-6. - DOI - PubMed
    1. Kimura T., Morimoto T., Nakagawa Y., et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-cypher registry. Circulation. 2012;125(4):584–591. doi: 10.1161/circulationaha.111.046599. - DOI - PubMed
    1. Byrne R. A., Kastrati A., Tiroch K., et al. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based cypher and endeavor, drug-eluting stents. Journal of the American College of Cardiology. 2010;55(23):2536–2543. doi: 10.1016/j.jacc.2010.03.020. - DOI - PubMed
    1. Nebeker J. R., Virmani R., Bennett C. L., et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. Journal of the American College of Cardiology. 2006;47(1):175–181. doi: 10.1016/j.jacc.2005.07.071. - DOI - PubMed
    1. Park S.-J., Kang S.-J., Virmani R., Nakano M., Ueda Y. In-stent neoatherosclerosis: a final common pathway of late stent failure. Journal of the American College of Cardiology. 2012;59(23):2051–2057. doi: 10.1016/j.jacc.2011.10.909. - DOI - PubMed

LinkOut - more resources